In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
The closing price of Xeris Biopharma Holdings Inc (NASDAQ: XERS) was $6.51 for the day, down -3.12% from the previous closing price of $6.72. In other words, the price has decreased by -$3.12 from its previous closing price. On the day, 2.04 million shares were traded. XERS stock price reached its highest trading level at $6.8 during the session, while it also had its lowest trading level at $6.47.
Ratios:
Our analysis of XERS’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 11.79 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 108.34. For the most recent quarter (mrq), Quick Ratio is recorded 1.35 and its Current Ratio is at 1.93.
On November 11, 2024, Piper Sandler Downgraded its rating to Neutral which previously was Overweight but kept the price unchanged to $3.
On March 28, 2024, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $5.Oppenheimer initiated its Outperform rating on March 28, 2024, with a $5 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Dec 01 ’25 when Hecht Beth sold 16,667 shares for $7.01 per share. The transaction valued at 116,781 led to the insider holds 1,320,176 shares of the business.
Shannon John Patrick Jr sold 23,242 shares of XERS for $173,402 on Nov 13 ’25. The insider now owns 2,643,153 shares after completing the transaction at $7.46 per share. On Nov 11 ’25, another insider, Hecht Beth, who serves as the insider of the company, sold 16,667 shares for $7.40 each. As a result, the insider received 123,296 and left with 1,336,843 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, XERS now has a Market Capitalization of 1080167168 and an Enterprise Value of 1246223104. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.06. Its current Enterprise Value per Revenue stands at 4.683 whereas that against EBITDA is 44.451.
Stock Price History:
The Beta on a monthly basis for XERS is 0.65, which has changed by 0.8033241 over the last 52 weeks, in comparison to a change of 0.13506866 over the same period for the S&P500. Over the past 52 weeks, XERS has reached a high of $10.08, while it has fallen to a 52-week low of $3.14. The 50-Day Moving Average of the stock is -19.79%, while the 200-Day Moving Average is calculated to be 7.00%.
Shares Statistics:
XERS traded an average of 2.38M shares per day over the past three months and 1884710 shares per day over the past ten days. A total of 165.53M shares are outstanding, with a floating share count of 154.66M. Insiders hold about 6.80% of the company’s shares, while institutions hold 58.99% stake in the company. Shares short for XERS as of 1763078400 were 15746194 with a Short Ratio of 6.61, compared to 1760486400 on 17850615. Therefore, it implies a Short% of Shares Outstanding of 15746194 and a Short% of Float of 9.86.
Earnings Estimates
. The current rating of Xeris Biopharma Holdings Inc (XERS) reflects the combined expertise of 1.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is $0.01, with high estimates of $0.01 and low estimates of $0.01.
Analysts are recommending an EPS of between -$0.04 and -$0.04 for the fiscal current year, implying an average EPS of -$0.04. EPS for the following year is $0.41, with 1.0 analysts recommending between $0.41 and $0.41.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 6 analysts. It ranges from a high estimate of $82.5M to a low estimate of $79M. As of. The current estimate, Xeris Biopharma Holdings Inc’s year-ago sales were $60.1MFor the next quarter, 6 analysts are estimating revenue of $83.23M. There is a high estimate of $86.9M for the next quarter, whereas the lowest estimate is $80.1M.
A total of 6 analysts have provided revenue estimates for XERS’s current fiscal year. The highest revenue estimate was $288.6M, while the lowest revenue estimate was $285M, resulting in an average revenue estimate of $287.42M. In the same quarter a year ago, actual revenue was $203.07MBased on 6 analysts’ estimates, the company’s revenue will be $367.52M in the next fiscal year. The high estimate is $432.3M and the low estimate is $337.9M.
